The mechanism of tumor response is that PD-1 inhibitors prevent the binding of protein PD-1 on the surface of activated T cells to PD-L1 and PD-L2 on the surface of tumor cells, thus restoring the function of T cells in the immune system. The gene discussed is PDCD1LG2; the disease is neoplasm.